(1350) Three-year Impact of Community Pharmacist-led Transitions of Care Model: A Retrospective Analysis

Objectives: ALTHOUGH RESEARCH HAS SHOWN THAT PHARMACISTS HAVE A POSITIVE IMPACT ON PATIENT OUTCOMES DURING TRANSITIONS OF CARE, THIS STUDY WILL LOOK SPECIFICALLY AT A COMMUNITY PHARMACIST-LED TRANSITIONS OF CARE MODEL. IN THIS MODEL, COMMUNITY-BASED PHARMACISTS HAVE AN EXPANDED ROLE BEYOND PROVIDING TRADITIONAL MEDICATION RECONCILIATION, AS PATIENTS ARE ALSO SCREENED FOR OTHER COMMON CHRONIC DISEASE STATES DIAGNOSED AND PROVIDED COMPREHENSIVE MEDICATION MANAGEMENT WITH SUBSEQUENT RECOMMENDATIONS PROPOSED TO THE PRIMARY CARE PROVIDER. The primary objective of this study is to assess the impact of THIS community pharmacist-led transitions of care model on 30-day readmission rates AND ESTIMATE the subsequent cost-effectiveness over a three-year period. ADDITIONALLY, the secondary objective is to evaluate THE provider acceptance rate of proposed recommendations, WHICH WILL PROVIDE VALUABLE INSIGHT, INCLUDING whether these services are being underutilized by PRIMARY CARE PROVIDERS. THIS STUDY WILL ALSO ASSESS IF TIMING OF TRANSITIONS OF CARE OUTREACH BY THE COMMUNITY PHARMACIST RELATIVE TO PRIMARY CARE PROVIDER FOLLOW-UP AFFECTS THE PROVIDER ACCEPTANCE RATE AND TO DETERMINE IF THERE ARE ANY TRENDS IN THE TYPES OF RECOMMENDATIONS IMPLEMENTED BY PROVIDERS.

Methods: This study is a retrospective chart review of transitions of care services completed by clinical pharmacists at an independent pharmacy BETWEEN 2020-2022. ALTHOUGH THIS STUDY PERIOD INCLUDES THE COVID-19 PANDEMIC, SERVICES WERE NOT PAUSED OR ALTERED SINCE PATIENTS WERE OUTREACHED VIA TELEHEALTH.

The intervention group are successful outreaches (COMPLETED TRANSITIONS OF CARE CONSULT), WHILE THE NON-INTERVENTION GROUP ARE THOSE who declined service or unreachable after four attempts. THE COMMUNITY pharmacist WOULD REVIEW the hospital study data QUARTERLY and collect INFORMATION FOR BOTH GROUPS INCLUDING: DISCHARGE DATE, DATES OF POST-DISCHARGE FOLLOW-UP(S), 30-DAY READMISSION, SUMMARY OF RECOMMENDATIONS, AND OUTCOMES, IF APPLICABLE. PRIOR TO DATA ANALYSIS, BOTH GROUPS WILL BE DE-IDENTIFIED.

FOR STATISTICAL CONSIDERATIONS OF THE PRIMARY-END POINT, 30-DAY READMISSION RATES WILL BE MEASURED AS "YES / NO" CATEGORICAL DATA AND ANALYZED VIA SIMPLE CHI-SQUARE TESTS. THE ESTIMATION OF COST-SAVINGS WILL BE DETERMINED VIA COST-BENEFIT ANALYSIS USING THE NUMBER OF HOSPITAL READMISSIONS PREVENTED AND EXTRAPOLATING THE AVERAGE COST OF READMISSION FROM PUBLISHED / PUBLIC DATA.

FOR STATISTICAL CONSIDERATIONS OF THE SECONDARY END-POINTS, PROVIDER ACCEPTANCE RATES WILL BE CALCULATED AS A PERCENTAGE BETWEEN YES (IMPLEMENTED) VS. NO (NOT IMPLEMENTED) CATEGORICAL DATA AND ANALYZED VIA SIMPLE CHI-SQUARE TESTS. ADDITIONALLY, LOGISTIC REGRESSION WILL BE USED TO ASSESS WHETHER TIMING OF POST-DISCHARGE FOLLOW-UP IMPACTS PROVIDER ACCEPTANCE RATES. THESE RESULTS WILL BE MEASURED AS A PERCENTAGE BETWEEN CATEGORICAL DATA VIA SIMPLE CHI-SQUARE TESTS. LASTLY, ACCEPTED RECOMMENDATIONS WILL BE CATEGORIZED BASED ON THE "TYPE OF INTERVENTION MADE"; FREQUENCY ANALYSIS WILL BE USED TO CATEGORIZE THE TOP PROVIDER-ACCEPTED RECOMMENDATIONS.

Results: N/A

Conclusions: N/A